OKYO PHARMA LIMITED
DIRECTORATE CHANGE
OKYO Pharma Limited ("OKYO" or the "Company") announces that Dr Kunwar Shailubhai has decided to stand down as a director of the Company with immediate effect to focus on his other executive appointments.
Gabriele Cerrone, Chairman of OKYO, said "I thank Dr Shailu for his contribution to the Board and the Company and appreciate that his other executive commitments mean that he is no longer able to take an active role going forward".
About OKYO
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
Enquiries:
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
Gabriele Cerrone, Non-Executive Chairman
+44 (0)20 7495 2379
Optiva Securities Limited
(Broker)
Robert Emmet
+44 (0)20 3981 4173
For further information, please visit the Company's website at www.okyopharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
